The renin-angiotensin system and cancer: Old dog, new tricks

Nature Reviews Cancer

Volumn 10, Issue 11, 2010, Pages 745-759

  George, Amee J ^a,b   Thomas, Walter G ^a   Hannan, Ross D ^b,c,d  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PETER MACCALLUM CANCER CENTRE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOTENSIN 1-7; ANGIOTENSIN RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANGIOGENESIS; APOPTOSIS; CANCER GROWTH; CANCER RESEARCH; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL; GENE MUTATION; HUMAN; IN VIVO STUDY; INFLAMMATION; METASTASIS; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SOLID TUMOR; TUMOR GROWTH;

HUMANS; NEOPLASMS; RENIN-ANGIOTENSIN SYSTEM;

EID: 77958502224     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2945     Document Type: Review

References (202)

1. Donoghue, M. et al. A novel angiotensin-convertingenzyme-related carboxypeptidase (ACE2) convertsangiotensin I to angiotensin 1-9. Circ. Res. 87, e1(2000).
2. Tipnis, S. R. et al. A human homolog of angiotensinconvertingenzyme. Cloning and functional expressionas a captopril-insensitive carboxypeptidase. J. Biol. Chem. 275, 33238-33243 (2000).
3. Lambert, D. W., Clarke, N. E. & Turner, A. J. Not justangiotensinases: new roles for the angiotensinconvertingenzymes. Cell. Mol. Life Sci. 67, 89-98(2010).
4. Albiston, A. L. et al. Therapeutic targeting of insulinregulatedaminopeptidase: heads and tails?Pharmacol. Ther. 116, 417-427 (2007).
5. Nguyen, G. & Muller, D. N. The biology of the (pro)renin receptor. J. Am. Soc. Nephrol 21, 18-23 (2010).
6. Kohlstedt, K. et al. Angiotensin-converting enzyme(ACE) dimerization is the initial step in the ACEinhibitor-induced ACE signaling cascade in endothelialcells. Mol. Pharmacol. 69, 1725-1732 (2006).
7. Jeunemaitre, X. Genetics of the human renin angiotensinsystem. J. Mol. Med. 86, 637-641 (2008).
8. Oro, C., Qian, H. & Thomas, W. G. Type 1 angiotensinreceptor pharmacology: signaling beyond G proteins. Pharmacol. Ther. 113, 210-226 (2007).
9. Rudnicki, M. & Mayer, G. Significance of geneticpolymorphisms of the renin-angiotensin-aldosteronesystem in cardiovascular and renal disease. Pharmacogenomics 10, 463-476 (2009).
10. Bader, M. Tissue renin-angiotensin-aldosteronesystems: targets for pharmacological therapy. Annu. Rev. Pharmacol. Toxicol. 50, 439-465 (2010).
11. Aplin, M., Bonde, M. M. & Hansen, J. L. Moleculardeterminants of angiotensin II type 1 receptor functionalselectivity. J. Mol. Cell. Cardiol. 46, 15-24 (2009).
12. De Gasparo, M., Catt, K. J., Inagami, T., Wright, J. W.& Unger, T. International union of pharmacology. XXIII. The angiotensin II receptors. Pharmacol. Rev. 52,415-472 (2000).
13. Hunyady, L. & Catt, K. J. Pleiotropic AT1 receptorsignaling pathways mediating physiological andpathogenic actions of angiotensin II. Mol. Endocrinol.20, 953-970 (2006).
14. Mehta, P. K. & Griendling, K. K. Angiotensin II cellsignaling: physiological and pathological effects in thecardiovascular system. Am. J. Physiol. Cell Physiol.292, C82-C97 (2007).
15. Yin, G., Yan, C. & Berk, B. C. Angiotensin II signalingpathways mediated by tyrosine kinases. Int. J. Biochem. Cell Biol. 35, 780-783 (2003).
16. Ohtsu, H. et al. Angiotensin II signal transductionthrough small GTP-binding proteins: mechanism andsignificance in vascular smooth muscle cells. Hypertension 48, 534-540 (2006).
17. Lefkowitz, R. J. & Whalen, E. J. β-arrestins: traffic copsof cell signaling. Curr. Opin. Cell Biol. 16, 162-168(2004).
18. Rajagopal, S., Rajagopal, K. & Lefkowitz, R. J. Teaching old receptors new tricks: biasing seventransmembranereceptors. Nature Rev. Drug Discov.9, 373-386 (2010).
19. Shah, B. H. & Catt, K. J. TACE-dependent EGFreceptor activation in angiotensin-II-induced kidneydisease. Trends Pharmacol. Sci. 27, 235-237 (2006).
20. Smith, N. J., Chan, H. W., Osborne, J. E., Thomas, W. G.& Hannan, R. D. Hijacking epidermal growth factorreceptors by angiotensin II: new possibilities forunderstanding and treating cardiac hypertrophy. Cell. Mol. Life Sci. 61, 2695-2703 (2004).
21. Suzuki, H. & Eguchi, S. Growth factor receptortransactivation in mediating end organ damage byangiotensin II. Hypertension 47, 339-340 (2006).
22. Daub, H., Weiss, F. U., Wallasch, C. & Ullrich, A. Roleof transactivation of the EGF receptor in signalling byG-protein-coupled receptors. Nature 379, 557-560(1996).
23. Prenzel, N. et al. EGF receptor transactivation byG-protein-coupled receptors requiresmetalloproteinase cleavage of proHB-EGF. Nature402, 884-888 (1999).
24. Ohtsu, H., Dempsey, P. J. & Eguchi, S. ADAMs asmediators of EGF receptor transactivation byG protein-coupled receptors. Am. J. Physiol. CellPhysiol. 291, C1-C10 (2006).
25. Shah, B. H. & Catt, K. J. Matrix metalloproteinasedependentEGF receptor activation in hypertensionand left ventricular hypertrophy. Trends Endocrinol. Metab. 15, 241-243 (2004).
26. Shah, B. H. et al. Differential pathways of angiotensin IIinducedextracellularly regulated kinase 1/2phosphorylation in specific cell types: role of heparinbindingepidermal growth factor. Mol. Endocrinol. 18,2035-2048 (2004).
27. Thomas, W. G. et al. Adenoviral-directed expression ofthe type 1A angiotensin receptor promotescardiomyocyte hypertrophy via transactivation of theepidermal growth factor receptor. Circ. Res. 90,135-142 (2002).
28. Albiston, A. L. et al. Evidence that the angiotensin IV(AT4) receptor is the enzyme insulin-regulatedaminopeptidase. J. Biol. Chem. 276, 48623-48626(2001).
29. Lyngso, C., Erikstrup, N. & Hansen, J. L. Functionalinteractions between 7TM receptors in the renin-angiotensin system-dimerization or crosstalk? Mol. Cell. Endocrinol. 302, 203-212 (2009).
30. Nguyen, G. The (pro)renin receptor in health anddisease. Ann. Med. 42, 13-18 (2010).
31. Porrello, E. R., Delbridge, L. M. & Thomas, W. G. Theangiotensin II type 2 (AT2) receptor: an enigmaticseven transmembrane receptor. Front. Biosci. 14,958-972 (2009).
32. Rompe, F., Unger, T. & Steckelings, U. M. Theangiotensin AT2 receptor in inflammation. Drug NewsPerspect. 23, 104-111 (2010).
33. Siragy, H. M. The potential role of the angiotensinsubtype 2 receptor in cardiovascular protection. Curr. Hypertens. Rep. 11, 260-262 (2009).
34. Steckelings, U. M., Kaschina, E. & Unger, T. The AT2receptor-a matter of love and hate. Peptides 26,1401-1409 (2005).
35. Ayoub, M. A. & Pfleger, K. D. Recent advances inbioluminescence resonance energy transfertechnologies to study GPCR heteromerization. Curr. Opin. Pharmacol. 10, 44-52 (2010).
36. Ferre, S. et al. Building a new conceptual frameworkfor receptor heteromers. Nature Chem. Biol. 5,131-134 (2009).
37. Unger, T. & Dahlof, B. Compound 21, the first orallyactive, selective agonist of the angiotensin type 2receptor (AT2): implications for AT2 receptor researchand therapeutic potential. J. Renin AngiotensinAldosterone Syst. 11, 75-77 (2010).
38. Wan, Y. et al. Design, synthesis, and biologicalevaluation of the first selective nonpeptide AT2receptor agonist. J. Med. Chem. 47, 5995-6008(2004).
39. Iwai, M. & Horiuchi, M. Role of renin-angiotensinsystem in adipose tissue dysfunction. Hypertens. Res.32, 425-427 (2009).
40. Lu, H., Rateri, D. L., Cassis, L. A. & Daugherty, A. Therole of the renin-angiotensin system in aorticaneurysmal diseases. Curr. Hypertens. Rep. 10,99-106 (2008).
41. Weiss, D., Sorescu, D. & Taylor, W. R. Angiotensin II andatherosclerosis. Am. J. Cardiol. 87, 25C-32C (2001).
42. Schiffrin, E. L. T lymphocytes: a role in hypertension?Curr. Opin. Nephrol. Hypertens. 19, 181-186 (2010).
43. Heringer-Walther, S. et al. Angiotensin-(1-7)stimulates hematopoietic progenitor cells in vitro andin vivo. Haematologica 94, 857-860 (2009).
44. Park, T. S. & Zambidis, E. T. A role for the renin-angiotensin system in hematopoiesis. Haematologica94, 745-747 (2009).
45. Zambidis, E. T. et al. Expression of angiotensinconvertingenzyme (CD143) identifies and regulatesprimitive hemangioblasts derived from humanpluripotent stem cells. Blood 112, 3601-3614(2008).
46. Lever, A. F. et al. Do inhibitors ofangiotensin-I-converting enzyme protect against riskof cancer? Lancet 352, 179-184 (1998).
47. Christian, J. B., Lapane, K. L., Hume, A. L., Eaton, C. B.& Weinstock, M. A. Association of ACE inhibitors andangiotensin receptor blockers with keratinocyte cancerprevention in the randomized VATTC trial. J. NatlCancer Inst. 100, 1223-1232 (2008).
48. Lang, L. ACE inhibitors may reduce esophagealcancer incidence. Gastroenterology 131, 343-344(2006).
49. Ronquist, G. et al. Association between captopril,other antihypertensive drugs and risk of prostatecancer. Prostate 58, 50-56 (2004).
50. Wilop, S. et al. Impact of angiotensin I convertingenzyme inhibitors and angiotensin II type 1 receptorblockers on survival in patients with advancednon-small-cell lung cancer undergoing first-lineplatinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 135, 1429-1435 (2009).
51. Paul, M., Poyan Mehr, A. & Kreutz, R. Physiology oflocal renin-angiotensin systems. Physiol. Rev. 86,747-803 (2006).
52. Rhodes, D. R. et al. AGTR1 overexpression defines asubset of breast cancer and confers sensitivity tolosartan, an AGTR1 antagonist. Proc. Natl Acad. Sci. USA 106, 10284-10289 (2009). Through extensive microarray data mining, theseauthors found AGTR1 to be overexpressed in asubset of breast cancers.
53. Kinoshita, J. et al. Local angiotensin II-generation inhuman gastric cancer: correlation with tumorprogression through the activation of ERK1/2, NF-κBand survivin. Int. J. Oncol. 34, 1573-1582 (2009).
54. Rocken, C. et al. The number of lymph nodemetastases in gastric cancer correlates with theangiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin. Cancer Res. 11,2526-2530 (2005).
55. Rocken, C. et al. The angiotensin II/angiotensin IIreceptor system correlates with nodal spread inintestinal type gastric cancer. Cancer Epidemiol. Biomarkers Prev. 16, 1206-1212 (2007).
56. Suganuma, T. et al. Functional expression of theangiotensin II type 1 receptor in human ovariancarcinoma cells and its blockade therapy resulting insuppression of tumor invasion, angiogenesis, andperitoneal dissemination. Clin. Cancer Res. 11,2686-2694 (2005).
57. Uemura, H. et al. Renin-angiotensin system is animportant factor in hormone refractory prostatecancer. Prostate 66, 822-830 (2006).
58. De Paepe, B., Verstraeten, V. L., De Potter, C. R.,Vakaet, L. A. & Bullock, G. R. Growth stimulatoryangiotensin II type-1 receptor is upregulated in breasthyperplasia and in situ carcinoma but not in invasivecarcinoma. Histochem. Cell Biol. 116, 247-254(2001).
59. Amaya, K. et al. Angiotensin II activates MAP kinaseand NF-κB through angiotensin II type I receptor inhuman pancreatic cancer cells. Int. J. Oncol. 25,849-856 (2004).
60. Doi, C. et al. Angiotensin II type 2 receptor signalingsignificantly attenuates growth of murine pancreaticcarcinoma grafts in syngeneic mice. BMC Cancer 10,67 (2010).
61. Egami, K. et al. Role of host angiotensin II type 1receptor in tumor angiogenesis and growth. J. Clin. Invest. 112, 67-75 (2003).
62. Using a Agtr1a-/-mouse model, this studydemonstrated that host AT1A is required fortumour growth and angiogenesis in vivo. Fujita, M. et al. Angiotensin type 1a receptorsignaling-dependent induction of vascular endothelialgrowth factor in stroma is relevant to tumorassociatedangiogenesis and tumor growth. Carcinogenesis 26, 271-279 (2005).
63. Imai, N. et al. Roles for host and tumor angiotensin IItype 1 receptor in tumor growth and tumor-associatedangiogenesis. Lab. Invest. 87, 189-198 (2007).
64. Rigat, B. et al. An insertion/deletion polymorphism inthe angiotensin I-converting enzyme gene accountingfor half the variance of serum enzyme levels. J. Clin. Invest. 86, 1343-1346 (1990).
65. Tiret, L. et al. Evidence, from combined segregationand linkage analysis, that a variant of the angiotensinI-converting enzyme (ACE) gene controls plasma ACElevels. Am. J. Hum. Genet. 51, 197-205 (1992).
66. Ebert, M. P. et al. The angiotensin I-converting enzymegene insertion/deletion polymorphism is linked toearly gastric cancer. Cancer Epidemiol. BiomarkersPrev. 14, 2987-2989 (2005).
67. Yigit, B. et al. Effects of ACE I/D polymorphism onprostate cancer risk, tumor grade and metastatis. Anticancer Res. 27, 933-936 (2007).
68. Medeiros, R. et al. Linkage of angiotensin I-convertingenzyme gene insertion/deletion polymorphism to theprogression of human prostate cancer. J. Pathol. 202,330-335 (2004).
69. Van der Knaap, R. et al. Renin-angiotensin systeminhibitors, angiotensin I-converting enzyme geneinsertion/deletion polymorphism, and cancer: theRotterdam Study. Cancer 112, 748-757 (2008).
70. Nikiteas, N., Tsigris, C., Chatzitheofylaktou, A. & Yannopoulos, A. No association with risk for colorectalcancer of the insertion/deletion polymorphism whichaffects levels of angiotensin-converting enzyme. In Vivo21, 1065-1068 (2007).
71. Sugimoto, M. et al. Influences of chymase andangiotensin I-converting enzyme gene polymorphismson gastric cancer risks in Japan. Cancer Epidemiol. Biomarkers Prev. 15, 1929-1934 (2006).
72. Freitas-Silva, M. et al. Angiotensin I-convertingenzyme gene insertion/deletion polymorphism andendometrial human cancer in normotensive andhypertensive women. Cancer Genet. Cytogenet. 155,42-46 (2004).
73. Gonzalez-Zuloeta Ladd, A. M. et al. Differential rolesof angiotensinogen and angiotensin receptor type 1polymorphisms in breast cancer risk. Breast CancerRes. Treat. 101, 299-304 (2007).
74. Vairaktaris, E. et al. Angiotensinogen polymorphism isassociated with risk for malignancy but not for oralcancer. Anticancer Res. 28, 1675-1679 (2008).
75. Koh, W. P., Yuan, J. M., Van Den Berg, D., Lee, H. P. & Yu, M. C. Polymorphisms in angiotensin II type 1receptor and angiotensin I-converting enzyme genesand breast cancer risk among Chinese women inSingapore. Carcinogenesis 26, 459-464 (2005).
76. Chen, J. et al. Genomic profiling of 766 cancer-relatedgenes in archived esophageal normal and carcinomatissues. Int. J. Cancer 122, 2249-2254 (2008).
77. Beroukhim, R. et al. Assessing the significance ofchromosomal aberrations in cancer: methodology andapplication to glioma. Proc. Natl Acad. Sci. USA 104,20007-20012 (2007).
78. Beroukhim, R. et al. The landscape of somatic copynumberalteration across human cancers. Nature 463,899-905 (2010).
79. Ohta, T. et al. Angiotensin converting enzymeindependent,local angiotensin II-generation in humanpancreatic ductal cancer tissues. Int. J. Oncol. 23,593-598 (2003).
80. Fujimoto, Y., Sasaki, T., Tsuchida, A. & Chayama, K. Angiotensin II type 1 receptor expression in humanpancreatic cancer and growth inhibition by angiotensinII type 1 receptor antagonist. FEBS Lett. 495,197-200 (2001).
81. Nickenig, G. & Harrison, D. G. The AT1-typeangiotensin receptor in oxidative stress andatherogenesis: part II: AT1 receptor regulation. Circulation 105, 530-536 (2002).
82. Brosnihan, K. B., Hodgin, J. B., Smithies, O.,Maeda, N. & Gallagher, P. Tissue-specific regulationof ACE/ACE2 and AT1/AT2 receptor gene expressionby oestrogen in apolipoprotein E/oestrogenreceptor-α knock-out mice. Exp. Physiol. 93,658-664 (2008).
83. Gallagher, P. E., Li, P., Lenhart, J. R., Chappell, M. C. & Brosnihan, K. B. Estrogen regulation of angiotensinconvertingenzyme mRNA. Hypertension 33,323-328 (1999).
84. Krishnamurthi, K. et al. Estrogen regulatesangiotensin AT1 receptor expression via cytosolicproteins that bind to the 5′ leader sequence of thereceptor mRNA. Endocrinology 140, 5435-5438(1999).
85. Nickenig, G. et al. Estrogen modulates AT1 receptorgene expression in vitro and in vivo. Circulation 97,2197-2201 (1998).
86. Wu, Z. et al. Estrogen regulates adrenal angiotensinAT1 receptors by modulating AT1 receptortranslation. Endocrinology 144, 3251-3261(2003).
87. Herr, D. et al. Potential role of renin-angiotensinsystem for tumor angiogenesis in receptor negativebreast cancer. Gynecol. Oncol. 109, 418-425 (2008).
88. Lim, K. T., Cosgrave, N., Hill, A. D. & Young, L. S. Nongenomic oestrogen signalling in oestrogenreceptor negative breast cancer cells: a role for theangiotensin II receptor AT1. Breast Cancer Res. 8,R33 (2006).
89. Croce, C. M. Causes and consequences of microRNAdysregulation in cancer. Nature Rev. Genet. 10,704-714 (2009).
90. Martin, M. M., Lee, E. J., Buckenberger, J. A.,Schmittgen, T. D. & Elton, T. S. MicroRNA-155regulates human angiotensin II type 1 receptorexpression in fibroblasts. J. Biol. Chem. 281,18277-18284 (2006).
91. Sethupathy, P. et al. Human microRNA-155 onchromosome 21 differentially interacts with itspolymorphic target in the AGTR1 3¢ untranslatedregion: a mechanism for functional single-nucleotidepolymorphisms related to phenotypes. Am. J. Hum. Genet. 81, 405-413 (2007).
92. Costinean, S. et al. Pre-B cell proliferation andlymphoblastic leukemia/high-grade lymphoma inEμ-miR155 transgenic mice. Proc. Natl Acad. Sci. USA103, 7024-7029 (2006).
93. Alves Correa, S. A. et al. Association between theangiotensin-converting enzyme (insertion/deletion)and angiotensin II type 1 receptor (A1166C)polymorphisms and breast cancer among Brazilianwomen. J. Renin Angiotensin Aldosterone Syst. 10,1151-1158 (2009).
94. Hanahan, D. & Weinberg, R. A. The hallmarks ofcancer. Cell 100, 57-70 (2000).
95. A landmark review discussing the various hallmarksof cancer biology. Heinzerling, J. H., Anthony, T., Livingston, E. H. & Huerta, S. Predictors of distant metastasis andmortality in patients with stage II colorectal cancer. Am. Surg. 73, 230-238 (2007).
96. Fujita, M., Hayashi, I., Yamashina, S., Itoman, M. & Majima, M. Blockade of angiotensin AT1a receptorsignaling reduces tumor growth, angiogenesis, andmetastasis. Biochem. Biophys. Res. Commun. 294,441-447 (2002).
97. Miyajima, A. et al. Angiotensin II type I antagonistprevents pulmonary metastasis of murine renal cancerby inhibiting tumor angiogenesis. Cancer Res. 62,4176-4179 (2002).
98. Attoub, S. et al. Captopril as a potential inhibitor oflung tumor growth and metastasis. Ann. N. Y. Acad. Sci. 1138, 65-72 (2008).
99. Ishimatsu, S. et al. Angiotensin II augmentedmigration and invasion of choriocarcinoma cellsinvolves PI3K activation through the AT1 receptor. Placenta 27, 587-591 (2006).
100. Carl-McGrath, S., Ebert, M. P., Lendeckel, U. & Rocken, C. Expression of the local angiotensin II systemin gastric cancer may facilitate lymphatic invasion andnodal spread. Cancer Biol. Ther. 6 1229-1237 (2007).
101. Berry, M. G., Goode, A. W., Puddefoot, J. R.,Vinson, G. P. & Carpenter, R. Integrin β1 upregulationin MCF-7 breast cancer cells by angiotensin II. Eur. J. Surg. Oncol. 26, 25-29 (2000).
102. Puddefoot, J. R., Udeozo, U. K., Barker, S. & Vinson, G. P. The role of angiotensin II in theregulation of breast cancer cell adhesion and invasion. Endocr. Relat. Cancer 13, 895-903 (2006).
103. Balkwill, F., Charles, K. A. & Mantovani, A. Smolderingand polarized inflammation in the initiation andpromotion of malignant disease. Cancer Cell 7,211-217 (2005).
104. Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436-444(2008).
105. Ager, E. I., Neo, J. & Christophi, C. The renin-angiotensin system and malignancy. Carcinogenesis29, 1675-1684 (2008).
106. Deshayes, F. & Nahmias, C. Angiotensin receptors: anew role in cancer? Trends Endocrinol. Metab. 16,293-299 (2005).
107. Smith, G. R. & Missailidis, S. Cancer, inflammation andthe AT1 and AT2 receptors. J. Inflamm. (Lond.) 1, 3(2004).
108. Andrade, S. P., Cardoso, C. C., Machado, R. D. & Beraldo, W. T. Angiotensin-II-induced angiogenesis insponge implants in mice. Int. J. Microcirc. Clin. Exp.16, 302-307 (1996).
109. Hu, D. E., Hiley, C. R. & Fan, T. P. Comparative studiesof the angiogenic activity of vasoactive intestinalpeptide, endothelins-1 and-3 and angiotensin II in arat sponge model. Br. J. Pharmacol. 117, 545-551(1996).
110. Le Noble, F. A., Hekking, J. W., Van Straaten, H. W.,Slaaf, D. W. & Struyker Boudier, H. A. Angiotensin IIstimulates angiogenesis in the chorio-allantoicmembrane of the chick embryo. Eur. J. Pharmacol.195, 305-306 (1991).
111. Le Noble, F. A. et al. Evidence for a novel angiotensin IIreceptor involved in angiogenesis in chick embryochorioallantoic membrane. Am. J. Physiol. 264,R460-R465 (1993).
112. Walsh, D. A. et al. Sequential development ofangiotensin receptors and angiotensin I convertingenzyme during angiogenesis in the rat subcutaneoussponge granuloma. Br. J. Pharmacol. 120,1302-1311 (1997).
113. Marrero, M. B. et al. Direct stimulation of Jak/STATpathway by the angiotensin II AT1 receptor. Nature375, 247-250 (1995).
114. Page, E. L., Robitaille, G. A., Pouyssegur, J. & Richard,D. E. Induction of hypoxia-inducible factor-1α bytranscriptional and translational mechanisms. J. Biol. Chem. 277, 48403-48409 (2002).
115. Ruiz-Ortega, M. et al. Angiotensin II activates nucleartranscription factor κB through AT1 and AT2 in vascularsmooth muscle cells: molecular mechanisms. Circ. Res.86, 1266-1272 (2000).
116. Pouyssegur, J., Dayan, F. & Mazure, N. M. Hypoxiasignalling in cancer and approaches to enforce tumourregression. Nature 441, 437-443 (2006).
117. Karin, M. Nuclear factor-κB in cancer developmentand progression. Nature 441, 431-436 (2006).
118. Haura, E. B., Turkson, J. & Jove, R. Mechanisms ofdisease: insights into the emerging role of signaltransducers and activators of transcription in cancer. Nature Clin. Pract. Oncol. 2, 315-324 (2005).
119. Arafat, H. A. et al. Antihypertensives as novelantineoplastics: angiotensin-I-converting enzymeinhibitors and angiotensin II type 1 receptor blockersin pancreatic ductal adenocarcinoma. J. Am. Coll. Surg. 204, 996-1006 (2007).
120. Chehl, N. et al. Angiotensin II regulates the expressionof monocyte chemoattractant protein-1 in pancreaticcancer cells. J. Gastrointest. Surg. 13, 2189-2200(2009).
121. Kosaka, T. et al. Ets-1 and hypoxia inducible factor-1αinhibition by angiotensin II type-1 receptor blockade inhormone-refractory prostate cancer. Prostate 70,162-169 (2010).
122. Kosugi, M., Miyajima, A., Kikuchi, E., Horiguchi, Y. & Murai, M. Angiotensin II type 1 receptor antagonistcandesartan as an angiogenic inhibitor in a xenograftmodel of bladder cancer. Clin. Cancer Res. 12,2888-2893 (2006).
123. Watanabe, Y. et al. Adipocyte-derived leucineaminopeptidase suppresses angiogenesis in humanendometrial carcinoma via renin-angiotensin system. Clin. Cancer Res. 9, 6497-6503 (2003).
124. Juillerat-Jeanneret, L. et al. Renin andangiotensinogen expression and functions in growthand apoptosis of human glioblastoma. Br. J. Cancer90, 1059-1068 (2004).
125. Uemura, H. et al. Antiproliferative activity ofangiotensin II receptor blocker through cross-talkbetween stromal and epithelial prostate cancer cells. Mol. Cancer Ther. 4, 1699-1709 (2005).
126. Neo, J. H., Malcontenti-Wilson, C., Muralidharan, V. & Christophi, C. Effect of ACE inhibitors andangiotensin II receptor antagonists in a mouse modelof colorectal cancer liver metastases. J. Gastroenterol. Hepatol. 22, 577-584 (2007).
127. Anandanadesan, R. et al. Angiotensin II inducesvascular endothelial growth factor in pancreatic cancercells through an angiotensin II type 1 receptor andERK1/2 signaling. J. Gastrointest. Surg. 12, 57-66(2008).
128. Huang, W. et al. Angiotensin II type 1 receptorantagonist suppress angiogenesis and growth ofgastric cancer xenografts. Dig. Dis. Sci. 53,1206-1210 (2008).
129. Kosaka, T. et al. Angiotensin II type 1 receptorantagonist as an angiogenic inhibitor in prostatecancer. Prostate 67, 41-49 (2007).
130. Noguchi, R. et al. Synergistic inhibitory effect ofgemcitabine and angiotensin type-1 receptor blocker,losartan, on murine pancreatic tumor growth via antiangiogenicactivities. Oncol. Rep. 22, 355-360(2009).
131. Wang, L. et al. Effects of angiotensin-convertingenzyme inhibitors and angiotensin II type 1 receptorblockers on lymphangiogenesis of gastric cancer in anude mouse model. Chin. Med. J. 121, 2167-2171(2008).
132. Yoshiji, H. et al. The angiotensin-I-converting enzymeinhibitor perindopril suppresses tumor growth andangiogenesis: possible role of the vascular endothelialgrowth factor. Clin. Cancer Res. 7, 1073-1078(2001).
133. Clere, N. et al. Deficiency or blockade of angiotensin IItype 2 receptor delays tumorigenesis by inhibitingmalignant cell proliferation and angiogenesis. Int. J. Cancer 127, 2279-2291 (2010).
134. Young, D., Waitches, G., Birchmeier, C., Fasano, O. & Wigler, M. Isolation and characterization of a newcellular oncogene encoding a protein with multiplepotential transmembrane domains. Cell 45, 711-719(1986).
135. Gallagher, P. E. & Tallant, E. A. Inhibition of humanlung cancer cell growth by angiotensin-(1-7).Carcinogenesis 25, 2045-2052 (2004).
136. Soto-Pantoja, D. R., Menon, J., Gallagher, P. E. & Tallant, E. A. Angiotensin-(1-7) inhibits tumorangiogenesis in human lung cancer xenografts with areduction in vascular endothelial growth factor. Mol. Cancer Ther. 8, 1676-1683 (2009).
137. Menon, J. et al. Angiotensin-(1-7) inhibits growth ofhuman lung adenocarcinoma xenografts in nude micethrough a reduction in cyclooxygenase-2. Cancer Res.67, 2809-2815 (2007).
138. Ermert, L., Dierkes, C. & Ermert, M. Immunohistochemical expression of cyclooxygenaseisoenzymes and downstream enzymes in human lungtumors. Clin. Cancer Res. 9, 1604-1610 (2003).
139. Huang, M. et al. Non-small cell lung cancercyclooxygenase-2-dependent regulation of cytokinebalance in lymphocytes and macrophages:up-regulation of interleukin 10 and down-regulation ofinterleukin 12 production. Cancer Res. 58,1208-1216 (1998).
140. Garrido, A. M. & Griendling, K. K. NADPH oxidasesand angiotensin II receptor signaling. Mol. Cell. Endocrinol. 302, 148-158 (2009).
141. Touyz, R. M., Yao, G., Viel, E., Amiri, F. & Schiffrin, E. L. Angiotensin II and endothelin-1 regulate MAP kinasesthrough different redox-dependent mechanisms inhuman vascular smooth muscle cells. J. Hypertens.22, 1141-1149 (2004).
142. Taniyama, Y. et al. Role of p38 MAPK andMAPKAPK-2 in angiotensin II-induced Akt activationin vascular smooth muscle cells. Am. J. Physiol. CellPhysiol. 287, C494-C499 (2004).
143. Touyz, R. M. et al. Redox-dependent MAP kinasesignaling by Ang II in vascular smooth muscle cells:role of receptor tyrosine kinase transactivation. Can. J. Physiol. Pharmacol. 81, 159-167 (2003).
144. Ushio-Fukai, M. et al. Reactive oxygen speciesmediate the activation of Akt/protein kinase B byangiotensin II in vascular smooth muscle cells. J. Biol. Chem. 274, 22699-22704 (1999).
145. Fruehauf, J. P. & Meyskens, F. L. Reactive oxygenspecies: a breath of life or death? Clin. Cancer Res.13, 789-794 (2007).
146. Fukui, T. et al. p22phox mRNA expression andNADPH oxidase activity are increased in aortas fromhypertensive rats. Circ. Res. 80, 45-51 (1997).
147. Landmesser, U. et al. Role of p47phox in vascularoxidative stress and hypertension caused byangiotensin II. Hypertension 40, 511-515 (2002).
148. Rajagopalan, S. et al. Angiotensin II-mediatedhypertension in the rat increases vascular superoxideproduction via membrane NADH/NADPH oxidaseactivation. Contribution to alterations of vasomotortone. J. Clin. Invest. 97, 1916-1923 (1996).
149. Virdis, A., Neves, M. F., Amiri, F., Touyz, R. M. & Schiffrin, E. L. Role of NAD(P)H oxidase on vascularalterations in angiotensin II-infused mice. J. Hypertens.22, 535-542 (2004).
150. Uemura, H. et al. Angiotensin II induces oxidativestress in prostate cancer. Mol. Cancer Res. 6,250-258 (2008).
151. Celerier, J., Cruz, A., Lamande, N., Gasc, J. M. & Corvol, P. Angiotensinogen and its cleaved derivativesinhibit angiogenesis. Hypertension 39, 224-228(2002).
152. Bouquet, C. et al. Suppression of angiogenesis, tumorgrowth, and metastasis by adenovirus-mediated genetransfer of human angiotensinogen. Mol. Ther. 14,175-182 (2006).
153. Vincent, F. et al. Angiotensinogen delays angiogenesisand tumor growth of hepatocarcinoma in transgenicmice. Cancer Res. 69, 2853-2860 (2009).
154. Chisi, J. E. et al. Captopril inhibits in vitro and in vivothe proliferation of primitive haematopoietic cellsinduced into cell cycle by cytotoxic drug administrationor irradiation but has no effect on myeloid leukaemiacell proliferation. Br. J. Haematol. 109, 563-570(2000).
155. De la Iglesia Iñigo, S. et al. Induction of apoptosis inleukemic cell lines treated with captopril, trandolapriland losartan: a new role in the treatment of leukaemiafor these agents. Leuk. Res. 33, 810-816 (2009).
156. Hii, S. I. et al. Captopril inhibits tumour growth in axenograft model of human renal cell carcinoma. Br. J. Cancer 77, 880-883 (1998).
157. Isobe, A. et al. Dual repressive effect of angiotensinII-type 1 receptor blocker telmisartan on angiotensinII-induced and estradiol-induced uterine leiomyomacell proliferation. Hum. Reprod. 23, 440-446 (2008).
158. Muscella, A., Greco, S., Elia, M. G., Storelli, C. & Marsigliante, S. Angiotensin II stimulation of Na+/K+ATPase activity and cell growth by calciumindependentpathway in MCF-7 breast cancer cells. J. Endocrinol. 173, 315-323 (2002).
159. Muscella, A., Greco, S., Elia, M. G., Storelli, C. & Marsigliante, S. PKC-zeta is required for angiotensinII-induced activation of ERK and synthesis of C-FOS inMCF-7 cells. J. Cell Physiol. 197, 61-68 (2003).
160. Greco, S. et al. Angiotensin II activates extracellularsignal regulated kinases via protein kinase C andepidermal growth factor receptor in breast cancercells. J. Cell. Physiol. 196, 370-377 (2003).
161. Itabashi, H. et al. Angiotensin II and epidermal growthfactor receptor cross-talk mediated by a disintegrinand metalloprotease accelerates tumor cellproliferation of hepatocellular carcinoma cell lines. Hepatol. Res. 38, 601-613 (2008).
162. Teranishi, J. et al. Evaluation of role of angiotensin IIIand aminopeptidases in prostate cancer cells. Prostate68, 1666-1673 (2008).
163. Uemura, H. et al. Angiotensin II receptor blockershows antiproliferative activity in prostate cancer cells:a possibility of tyrosine kinase inhibitor of growthfactor. Mol. Cancer Ther. 2, 1139-1147 (2003).
164. Arrieta, O. et al. Blockage of angiotensin II type Ireceptor decreases the synthesis of growth factors andinduces apoptosis in C6 cultured cells and C6 ratglioma. Br. J. Cancer 92, 1247-1252 (2005).
165. Zhao, Y. et al. Angiotensin II / angiotensin II type Ireceptor (AT1R) signaling promotes MCF-7 breastcancer cells survival via PI3-kinase/Akt pathway. J. Cell. Physiol. (2010).
166. Zhou, L. et al. Decreased expression of angiotensinconvertingenzyme 2 in pancreatic ductaladenocarcinoma is associated with tumor progression. Tohoku J. Exp. Med. 217, 123-131 (2009).
167. Zhao, Y. et al. Angiotensin II suppresses adriamycininducedapoptosis through activation ofphosphatidylinositol 3-kinase/Akt signaling in humanbreast cancer cells. Acta Biochim. Biophys. Sin.(Shanghai) 40, 304-310 (2008).
168. Li, X., Zhang, H., Soledad-Conrad, V., Zhuang, J. & Uhal, B. D. Bleomycin-induced apoptosis of alveolarepithelial cells requires angiotensin synthesis De novo. Am. J. Physiol. Lung Cell. Mol. Physiol. 284,L501-L507 (2003).
169. Papp, M., Li, X., Zhuang, J., Wang, R. & Uhal, B. D. Angiotensin receptor subtype AT1 mediates alveolarepithelial cell apoptosis in response to ANG II. Am. J. Physiol. Lung Cell. Mol. Physiol. 282, L713-L718(2002).
170. Wang, R. et al. Apoptosis of lung epithelial cells inresponse to TNF-α requires angiotensin II generationde novo. J. Cell. Physiol. 185, 253-259 (2000).
171. Li, H. et al. Angiotensin type 2 receptor-mediatedapoptosis of human prostate cancer cells. Mol. CancerTher. 8, 3255-3265 (2009).
172. Pickel, L. et al. Overexpression of angiotensin II type 2receptor gene induces cell death in lung adenocarcinomacells. Cancer Biol. Ther. 9, 277-285 (2010).
173. Neo, J. H. et al. Changes in the renin angiotensinsystem during the development of colorectal cancerliver metastases. BMC Cancer 10, 134 (2010).
174. Otake, A. H. et al. Inhibition of angiotensin IIreceptor 1 limits tumor-associated angiogenesis andattenuates growth of murine melanoma. CancerChemother. Pharmacol. 66, 79-87 (2010).
175. Rivera, E., Arrieta, O., Guevara, P., Duarte-Rojo, A. & Sotelo, J. AT1 receptor is present in glioma cells; itsblockage reduces the growth of rat glioma. Br. J. Cancer 85, 1396-1399 (2001).
176. Volpert, O. V. et al. Captopril inhibits angiogenesis andslows the growth of experimental tumors in rats. J. Clin. Invest. 98, 671-679 (1996).
177. Uemura, H. et al. Pilot study of angiotensin II receptorblocker in advanced hormone-refractory prostatecancer. Int. J. Clin. Oncol. 10, 405-410 (2005).
178. Petty, W. J. et al. Phase I and pharmacokinetic studyof angiotensin-(1-7), an endogenous antiangiogenichormone. Clin. Cancer Res. 15, 7398-7404 (2009).
179. Luque, M. et al. Effects of captopril related toincreased levels of prostacyclin and angiotensin-(1-7)in essential hypertension. J. Hypertens. 14, 799-805(1996).
180. Moscarelli, L. et al. Keratinocyte cancer preventionwith ACE inhibitors, angiotensin receptor blockers ortheir combination in renal transplant recipients. Clin. Nephrol. 73, 439-445 (2010).
181. Fryzek, J. P. et al. A cohort study of antihypertensivemedication use and breast cancer among Danishwomen. Breast Cancer Res. Treat. 97, 231-236(2006).
182. Li, C. I. et al. Relation between use of antihypertensivemedications and risk of breast carcinoma amongwomen ages 65-79 years. Cancer 98, 1504-1513(2003).
183. Meier, C. R., Derby, L. E., Jick, S. S. & Jick, H. Angiotensin-converting enzyme inhibitors, calciumchannel blockers, and breast cancer. Arch. Intern. Med. 160, 349-353 (2000).
184. Perron, L., Bairati, I., Harel, F. & Meyer, F. Antihypertensive drug
185. Sipahi, I., Debanne, S. M., Rowland, D. Y., Simon, D. I.& Fang, J. C. Angiotensin-receptor blockade and riskof cancer: μ-analysis of randomised controlled trials. Lancet Oncol. 11, 627-636 (2010).
186. Timmermans, P. B. Angiotensin II receptorantagonists: an emerging new class of cardiovasculartherapeutics. Hypertens. Res. 22, 147-153 (1999).
187. Arora, P., Cuevas, B. D., Russo, A., Johnson, G. L. & Trejo, J. Persistent transactivation of EGFR and ErbB2/HER2 by protease-activated receptor-1 promotesbreast carcinoma cell invasion. Oncogene 27,4434-4445 (2008).
188. Gschwind, A., Hart, S., Fischer, O. M. & Ullrich, A. TACE cleavage of proamphiregulin regulates GPCRinducedproliferation and motility of cancer cells. EMBO J. 22, 2411-2421 (2003).
189. Gschwind, A., Prenzel, N. & Ullrich, A. Lysophosphatidic acid-induced squamous cellcarcinoma cell proliferation and motility involvesepidermal growth factor receptor signaltransactivation. Cancer Res. 62, 6329-6336 (2002).
190. Elenbaas, B. et al. Human breast cancer cellsgenerated by oncogenic transformation of primarymammary epithelial cells. Genes Dev. 15, 50-65(2001).
191. Suzuki, Y. et al. Inflammation and angiotensin II. Int. J. Biochem. Cell Biol. 35, 881-900 (2003).
192. Ino, K. et al. Angiotensin II type 1 receptor expressionin ovarian cancer and its correlation with tumourangiogenesis and patient survival. Br. J. Cancer 94,552-560 (2006).
193. Kikkawa, F. et al. Activation of invasiveness of cervicalcarcinoma cells by angiotensin II. Am. J. Obstet. Gynecol. 190, 1258-1263 (2004).
194. Inwang, E. R. et al. Angiotensin II type 1 receptorexpression in human breast tissues. Br. J. Cancer 75,1279-1283 (1997).
195. Tahmasebi, M., Barker, S., Puddefoot, J. R. & Vinson, G. P. Localisation of renin-angiotensin system(RAS) components in breast. Br. J. Cancer 95, 67-74(2006).
196. Chow, L. et al. Functional angiotensin II type 2receptors inhibit growth factor signaling in LNCaP andPC3 prostate cancer cell lines. Prostate 68, 651-660(2008).
197. Louis, S. N. et al. Appearance of angiotensin IIexpression in non-basal epithelial cells is an earlyfeature of malignant change in human prostate. Cancer Detect. Prev. 31, 391-395 (2007).
198. Marsigliante, S. et al. AT1 angiotensin II receptorsubtype in the human larynx and squamous laryngealcarcinoma. Cancer Lett. 110, 19-27 (1996).
199. Takeda, H. & Kondo, S. Differences between squamouscell carcinoma and keratoacanthoma in angiotensintype-1 receptor expression. Am. J. Pathol. 158,1633-1637 (2001).
200. Koh, W. P. et al. Angiotensin I-converting enzyme(ACE) gene polymorphism and breast cancer riskamong Chinese women in Singapore. Cancer Res. 63,573-578 (2003).
201. Gonzalez-Zuloeta Ladd, A. M. et al. Angiotensinconvertingenzyme gene insertion/deletionpolymorphism and breast cancer risk. CancerEpidemiol. Biomarkers Prev. 14, 2143-2146(2005).
202. Haiman, C. A., Henderson, S. O., Bretsky, P.,Kolonel, L. N. & Henderson, B. E. Genetic variation inangiotensin I-converting enzyme (ACE) and breastcancer risk: the multiethnic cohort. Cancer Res. 63,6984-6987 (2003).